|
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease Clinical research trials and Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease. Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease  Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
For Condition: AIDS-Related Lymphoma,HIV-associated Hodgkin's disease
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Ireland Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with lomustine, etoposide, cyclophosphamide, and procarbazine in treating patients with stage IIB, stage III, or stage IV AIDS-related Hodgkin's disease.
Details: OBJECTIVES: I. Determine the objective response rate, response duration, and survival of patients receiving lomustine/etoposide/cyclophosphamide/procarbazine (CECP) for stage IIB-IV AIDS-related Hodgkin's disease. II. Assess the feasibility and toxic effects of CECP in this patient population. PROTOCOL OUTLINE: Patients receive oral lomustine on day 1, oral etoposide on days 1-3, and oral cyclophosphamide and procarbazine on days 22-31. Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42. The course is repeated every 6 weeks. Patients with a complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course. Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy. Patients failing to respond after 1 course are removed from the study. Patients will be followed every 3 months until death. PROJECTED ACCRUAL: A minimum of 16 evaluable patients will be accrued.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically proven stage IIB-IV AIDS-related Hodgkin's disease - Patients with Hodgkin's disease as the only HIV-related condition must have a positive ELISA for HIV confirmed by Western Blot Measurable or evaluable disease No cytologic or radiologic evidence of CNS involvement --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: - No prior chemotherapy for Hodgkin's disease - At least 4 weeks since chemotherapy for Kaposi's sarcoma Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy for localized stage I or II disease that has progressed beyond initial radiation ports is allowed Surgery: Not specified Other: Concurrent AZT therapy is allowed --Patient Characteristics-- Age: Any age Performance Status: ECOG 0-3 Life Expectancy: At least 6 weeks Hematopoietic: - WBC at least 1,500/mm3 - Platelet count at least 50,000/mm3 Hepatic: Bilirubin no greater than 3.0 mg/dL Renal: Creatinine no greater than 3.0 mg/dL Other: Active infection is allowed (provided prognosis is estimated to be at least 6 weeks)
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ScotRemick, Study Chair, Ireland Cancer Center
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
Additional Information:
Study ID Numbers: CDR0000065864; CWRU-2496,NCI-G97-1351,AMC-4A-90
Study Start Date: July 1997
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003114
Other Aids-Related Lymphoma Studies:
1. Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection
2. Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma
3. Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
Related Studies:
Other AIDS-Related Lymphoma Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
|
|
|
|
|
|
|
|
